CN102357134A - Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof - Google Patents
Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof Download PDFInfo
- Publication number
- CN102357134A CN102357134A CN2011103310114A CN201110331011A CN102357134A CN 102357134 A CN102357134 A CN 102357134A CN 2011103310114 A CN2011103310114 A CN 2011103310114A CN 201110331011 A CN201110331011 A CN 201110331011A CN 102357134 A CN102357134 A CN 102357134A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- flos carthami
- cerebral thrombosis
- semen persicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 206010008132 Cerebral thrombosis Diseases 0.000 title claims abstract description 24
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title abstract description 39
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 6
- 229930003944 flavone Natural products 0.000 claims abstract description 25
- 235000011949 flavones Nutrition 0.000 claims abstract description 25
- 229930187479 gypenoside Natural products 0.000 claims abstract description 23
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 52
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 51
- 241000180649 Panax notoginseng Species 0.000 claims description 51
- 241000628997 Flos Species 0.000 claims description 40
- 210000000582 semen Anatomy 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 31
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 24
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 24
- 150000002212 flavone derivatives Chemical class 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 239000008187 granular material Substances 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000013467 fragmentation Methods 0.000 claims description 15
- 238000006062 fragmentation reaction Methods 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 6
- 241000219780 Pueraria Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 150000002213 flavones Chemical class 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- -1 flavone compound Chemical class 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 11
- 206010013786 Dry skin Diseases 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000003064 anti-oxidating effect Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to Chinese medicinal herb, in particular to a medicine for preventing and treating Alzheimer disease and cerebral thrombosis and a preparation method thereof, which belong to the field of medicines. The preparation mainly comprises the following raw materials by weight: 30-120 parts of pseudo-ginseng, 30-120 parts of Ligusticum wallichii, 30-120 parts of safflower carthamus, 30-120 parts of peach kernel, 90-360 parts of kudzuvine root, 50-150 parts of total flavones and 50-150 parts of Gypenoside. The preparation mainly used for preventing and treating the Alzheimer disease and the cerebral thrombosis.
Description
Technical field:
The present invention relates to a kind ofly with Chinese herbal medicine, definitely saying so is used to medicine that prevents and treat Alzheimer and cerebral thrombosis and preparation method thereof, belongs to drug world.
Background technology:
Alzheimer (AD); Claim alzheimer disease again; Be a kind of be the neurodegenerative disease of characteristic with concealment onset and deterioration of carrying out property or persistence hypophrenia; The category that belongs to organic mental sickness seriously reduction patient's quality of life, causes serious financial burden and stress for family and society.Many diseases of AD are in the geratic period, and every increase of age is 5 years old after 65 years old, and prevalence doubles.Along with the fast development of social population's aging, the proportion of old people in the crowd is increasing, and AD will become a very important health and social problem.
The AD pathogenesis is complicated, and the medicine that has gone on the market at present mainly is divided into two kinds, and a kind of is cholinesterase inhibitor, and example hydrochloric acid donepezil, galantamine, tartaric acid Rivastigmine, huperzine are first-class; Another kind is an excitatory amino acid receptor antagonists, the example hydrochloric acid memantine.Other has antiinflammatory, antioxidation, anti-cholesterol, directed against amyloid-beta protein medicaments to be used for the auxiliary treatment of AD.Said medicine can short-term be improved AD patient's symptom, but can not alleviate advancing of disease.Chinese medicine begins to receive the concern of Chinese scholars in recent years because of many target spots, too many levels and multimode mechanism of action.
Senile dementia belongs to Chinese medicine " dementia " categories such as " forgetful ", how because of the imbalance of liver functions such as vital essence loss, YANG-orifices failing to be nourished or the heart, liver, spleen, causes gas, blood, expectorant, fire, all evil retardance brain keys of the stasis of blood and forms.The patient is clinical mainly to be shown as slow-wittedly, stupid, stupid, stupid, and the Therapeutic Principle mainly contains that tonify deficiency is set upright, blood circulation promoting and blood stasis dispelling etc.
Cerebral thrombosis is a brain under slow blood flow, condition that blood pressure is on the low side, and blood formed element is more common in middle-aged and elderly people attached to film formed thrombosis in the tremulous pulse.Cerebral thrombosis is claimed cerebral infarction again; " apoplexy " category that belongs to Chinese medicine; How form because of gas, blood, wind, the stagnation of phlegm meridians that stagnate; Patient's onset is slower, and clinical manifestation is obstacles such as language, motor function, psychology and emotion in various degree, brings heavy financial burden and stress equally for family and society with AD patient.The Therapeutic Principle is mainly blood circulation promoting and blood stasis dispelling, promoting of the circulation of QI and removing the obstruction in the collaterals, suppressing the hyperactive liver and reduces phlegm etc.
Summary of the invention:
The purpose of this invention is to provide and be used to medicine that prevents and treat Alzheimer and cerebral thrombosis and preparation method thereof, the present invention has the cerebral blood flow increasing amount, and microcirculation improvement strengthens the tolerance to cerebral ischemia, and it is active to improve antioxidant system; Reduce WBV and plasma viscosity, effects such as anticoagulant and thrombosis.
Technical scheme of the present invention is used to prevent and treat the medicine of Alzheimer and cerebral thrombosis, and it is characterized in that: its raw material mainly is made up of the following weight ratio:
Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part.
Its raw material is made up of the following weight ratio:
49 parts of Radix Notoginseng, 49 parts of Rhizoma Chuanxiongs, 57.5 parts on Flos Carthami, 57.5 parts in Semen Persicae, 164 parts of Radix Puerariaes.
Its raw material is made up of the following weight ratio:
Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part, Fructus Crataegi flavone 50-150 part, gypenoside 50-150 part.
Its raw material weight ratio is:
49 parts of Radix Notoginseng, 49 parts of Rhizoma Chuanxiongs, 57.5 parts on Flos Carthami, 57.5 parts in Semen Persicae, 164 parts of Radix Puerariaes, 90 parts of Fructus Crataegi flavone, 90 parts of gypenosides.
Its described medicine is used for prevention and treatment Alzheimer and cerebral thrombosis.
Be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis, it is characterized in that: get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part; Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part; Medical material is made only fragmentation;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously; 60-80 ℃ of drying, dried cream powder is broken to sieve, and processes medicine by the industry routine.
Be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis; It is characterized in that: get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part; Semen Persicae 30-120 part; Radix Puerariae 90-360 part, Fructus Crataegi flavone 50-150 part, gypenoside 50-150 part; Medical material is made only fragmentation;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously, 60-80 ℃ of drying, dried cream powder is broken to sieve; With Fructus Crataegi flavone, gypenoside mix homogeneously according to the above ratio, process medicine by the industry routine.
Wherein said medicine is tablet, capsule, granule.
Characteristics of the present invention:
Theory of Chinese medical science:
The present invention be at distinguished veteran doctors of TCM on the basis of proved recipe, test resulting preparation through a large amount of preparation technologies.Medicine of the present invention is mainly the extract of Radix Puerariae, Radix Notoginseng, Rhizoma Chuanxiong, Semen Persicae, Flos Carthami.Wherein Radix Puerariae is hot, sweet, cool, returns spleen, stomach warp.Xin Zeneng looses, and the tonification of sweet ability is so can mend precise and tiny by qi and blood circulation promotion; Radix Notoginseng sweet in the mouth, little hardship are returned liver, stomach warp, but blood stasis dispelling and just not hindering.Two medicines share, and the merit that qi and blood circulation promotion, blood stasis dispelling stagnate is better, is monarch drug altogether.The hot temperature rise of Rhizoma Chuanxiong is diffusing, is " gas medicine in the blood ", and top, the sensible top of the up head of ability, the function blood-activating and qi-promoting, wind-expelling pain-stopping helps Radix Puerariae, pseudo-ginseng blood-circulation-invigovating regulating qi to disperse stagnation, removing obstruction in the collateral to relieve pain, and the up arrival brain of ability priming, is ministerial drug.Semen Persicae, Flos Carthami help Radix Puerariae, Radix Notoginseng, Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling, and removing obstruction in the collateral to relieve pain is adjuvant drug.
Another characteristics of the present invention are on the said medicine basis, increase the higher natural drug extract of purity, play the effect that strengthens effect of drugs.Wherein nourish heart spleen invigorating, QI invigorating and blood regulating, expectorant blood stasis dispelling, blood fat reducing of gypenoside cooperates the Radix Puerariae yang invigorating, plays the effect of setting upright simultaneously; Fructus Crataegi flavone is returned spleen, stomach, Liver Channel, and the circulation of qi promoting dissipating blood stasis is good for the stomach.Full side share, promoting flow of QI and blood, and disperse blood stasis and dredge collateral, strengthening vital QI to eliminate pathogenic factors is applicable to the prevention and the treatment of Alzheimer, can be used for the prevention and the treatment of cerebral thrombosis simultaneously.Compare with Western medicine, good effect of the present invention, toxic and side effects is little, expense is low, is worth clinical application.
Modern study:
Alzheimer disease pathologic is characterized as senile plaque (a is assembled formation), neurofibrillary tangles (Tau abnormal protein phosphatization).Oxidation can induce a to assemble, and NFT forms the position has proteinic oxidation product, explains that oxidation participated in the whole course of disease of AD.Therefore can be from improving brain blood flow state, the formation of antagonism oxidation reaction two aspects inhibition senile plaque, the effect of prevention and treatment AD is played by neuroprotective unit.
Radix Puerariae mainly contains flavone compound, can improve the oxygen metabolism of cardiac muscle, while ability blood vessel dilating, and microcirculation improvement reduces vascular resistance, and blood flow is increased, and hypertension, hyperlipidemia, hyperglycemia and cardiovascular and cerebrovascular disease are had significant curative effect.Wherein Radix Puerariae isoflavone can effectively stop the incidence and development of lipid peroxidation in cerebral tissue and the serum, and the SOD in vivo enhancement activity intensity, and animal groups is woven with the better protect effect; Puerarin can resist the neurotoxicity of amyloid beta protein, and the learning and memory achievement of model mice is improved.
Radix Notoginseng mainly contains saponins compound, and the ability expansion of cerebral vascular strengthens cerebrovascular flow, has antioxidation, antiinflammatory, the anti-ageing effect of waiting for a long time.Notoginseng saponins Rg 1 can reduce the content of AChE activity, MDA and lipofuscin in the cerebral cortex, with study, the memory function of improving brain.
Rhizoma Chuanxiong mainly contains alkaloid compound, and the ability expansion of cerebral vascular reduces vascular resistance, significantly increases brain and LBF amount, and microcirculation improvement reduces surface activity of blood platelet, suppresses platelet aggregation, the formation of prevention thrombosis.Ligustrazine can make D-ga1 and NaNO
2Combined induction, AlCl
3Induce two kinds of AD model mouse escape latency to shorten, the active reduction of AChE in the cerebral tissue, the active raising of SOD, MDA content reduce, and can obviously reduce A in two kinds of AD model mouse cerebral tissue
β, NF-
κThe expression of B.
Flos Carthami mainly contains flavone compound, the ability anticoagulant, and the fortifying fibre protein dissolution reduces WBV; Injection, ethanol extract, saffloside can significantly improve hypoxia-bearing capability, and the weary oxygen encephalopathy (HIE) of ischemia is had protective effect.Carthamus yellow wherein has the effect of tangible removing free radical.
The obvious cerebral blood flow increasing amount of Semen Persicae ability can make hemorrhage and clotting time obviously prolongs, and external thrombus is had inhibitory action, and fiber promotion, antioxidation, antiinflammatory, antibiotic, anti-allergic effects are arranged.The protein PR-B that is separated in its water-soluble component has great SOD appearance active.
The gypenoside blood pressure lowering, blood fat reducing, blood sugar lowering, arteriosclerosis, inhibition thrombosis, the activity of all right enhances human body blood medium-sized lymphocyte, the immunologic function of enhances human body.Can improve AD rat model ability of learning and memory.
Fructus Crataegi flavone has more persistent antioxidation; More sure effect for reducing fat is arranged.Can reduce the area of cerebral ischemic reperfusion in rats cerebral infarction, reduce the expression of MMP-9, the performance cerebral protection.
The present invention has the cerebral blood flow increasing amount, and microcirculation improvement strengthens the tolerance to cerebral ischemia, and it is active to improve antioxidant system; Reduce WBV and plasma viscosity, effects such as anticoagulant and thrombosis.
The specific embodiment
Be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis, get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part is made medical material fragmentation only;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously; 60-80 ℃ of drying, dried cream powder is broken to sieve, and processes medicine by the industry routine.
Be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis, get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part; Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part; Fructus Crataegi flavone 50-150 part, gypenoside 50-150 part; Medical material is made only fragmentation;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously, 60-80 ℃ of drying, dried cream powder is broken to sieve; With Fructus Crataegi flavone, gypenoside mix homogeneously according to the above ratio, process medicine by the industry routine.
Below in conjunction with embodiment the present invention is further specified, following each embodiment only is used to the present invention is described and is not limitation of the present invention that the method for preparing of wherein not narrating all is according to the conventional preparation of industry.
Embodiment 1: the preparation of tablet
Get crude drug by weight proportion: Radix Notoginseng 120g, Rhizoma Chuanxiong 120g, Flos Carthami 120g, Semen Persicae 120g, Radix Puerariae 360g.
1, medical material is made only
Radix Notoginseng: pick and remove impurity, fragmentation;
Rhizoma Chuanxiong: pick and remove impurity, section;
Flos Carthami: gauze is decocted a drug wrapped;
Semen Persicae: pick and remove impurity, smash to pieces;
Radix Puerariae: pick and remove impurity, section;
2, extraction process is confirmed
Selection water is extraction solvent, carries out the test of four factors, three horizontal quadratures.Four factors are followed successively by extraction time (h), extraction time, amount of water, blank.Three levels of every factor.Thick paste amount (weight coefficient 0.3) and index thing content (weight coefficient 0.7) with product are criterion, carry out statistical analysis, draw best extraction production technology.The Orthogonal Experiment and Design scheme is seen table 1, and result of the test is seen table 2, and The results of analysis of variance is seen table 3.
Table 1 extraction process orthogonal design factor level table
Table 2 extraction process L
9(3)
4Orthogonal experiments
Table 3 extraction process orthogonal test The results of analysis of variance
Result of the test shows that the influence factor is followed successively by B＞A＞C from big to small, and wherein the B factor has highly significant property (＜0.01) to test, and the A factor has significance (＜0.05), and the C factor is less to the test influence.Orthogonal table shows that optimum extraction process is A
2B
2C
2, but data show C
1And C
2Be more or less the same, consider from the angle of practicing thrift cost, final optimization technology is that 8 times of water gagings decoct 2 times, each 2 hours, i.e. and A
2B
2C
1Optimum condition in view of the above, pair of orthogonal experiment selection process verifies that the result sees table 4:
Table 4 extraction process orthogonal test selection process checking result
| Numbering | Inventory (g) | Paste volume (g) | Content (%) |
| 1 | 720 | 743.50 | 0.44 |
| 2 | 720 | 728.10 | 0.48 |
| 3 | 720 | 733.35 | 0.46 |
3. dry
The subsequent use medicinal liquid that extracts is at temperature 70-90 ℃, and under the vacuum 0.03-0.07Mpa, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, 70 ℃ of dryings, and dried cream is pulverized, and crosses 100 mesh sieves, and is subsequent use.
4. mix
Get dried cream powder and the Radix Notoginseng fine powder mixes according to the equivalent incremental method, promptly get.
5. the selection of wetting agent
Because of medicine viscosity ratio of the present invention is bigger, need to adopt suitable wetting agent system soft material, the present invention has selected the ethanol and the Different concentrations of alcohol system soft material of employing to carry out the screening of suitable wetting agent, and 14 purpose stainless steel meshs are granulated, 60 ℃ of dryings, the result sees table 5:
Table 5 different concentration ethanol result of the test
| Concentration of alcohol | Character | Soft material viscosity | The granule homogeneity | Pellet hardness | The tabletting quality |
| 80％ | Color and luster is uneven | Greatly | Generally | Greatly | Difference |
| 85％ | Color and luster is uneven | Greatly | Generally | Greatly | Generally |
| 90％ | Color and luster is consistent | Moderate | Uniform particles | Moderate | Well |
| 95％ | Color and luster is uneven | Little | Generally | Little | Generally |
The result shows that uniform particles, hardness that 90% ethanol makes are moderate, and the quality of tabletting is better, so select it for use.
In sum, this preparation process is confirmed as: medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and adds suitable adjuvant, stirs, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 2: the preparation of tablet
Get crude drug by weight proportion: Radix Notoginseng 30g, Rhizoma Chuanxiong 30g, Flos Carthami 30g, Semen Persicae 30g, Radix Puerariae 90g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and adds suitable adjuvant, stirs, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 3: the preparation of tablet
Get crude drug by weight ratio: Radix Notoginseng 49g, Rhizoma Chuanxiong 49g, Flos Carthami 57.5g, Semen Persicae 57.5g, Radix Puerariae 164g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and adds suitable adjuvant, stirs, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 4: the preparation of tablet
Get crude drug by weight proportion: Radix Notoginseng 120g, Rhizoma Chuanxiong 120g, Flos Carthami 120g, Semen Persicae 120g, Radix Puerariae 360g, Fructus Crataegi flavone 150g, gypenoside 150g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and Fructus Crataegi flavone, gypenoside mix homogeneously with according to the above ratio add suitable adjuvant, stir, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 5: the preparation of tablet
Get crude drug by weight proportion: Radix Notoginseng 49g, Rhizoma Chuanxiong 49g, Flos Carthami 57.5g, Semen Persicae 57.5g, Radix Puerariae 164g, Fructus Crataegi flavone 90g, gypenoside 90g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and Fructus Crataegi flavone, gypenoside mix homogeneously with according to the above ratio add suitable adjuvant, stir, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 6: the preparation of tablet
Radix Notoginseng 60g, Rhizoma Chuanxiong 60g, Flos Carthami 65g, Semen Persicae 65g, Radix Puerariae 180g, Fructus Crataegi flavone 75g, gypenoside 75g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and Fructus Crataegi flavone, gypenoside mix homogeneously with according to the above ratio add suitable adjuvant, stir, granulate, granulate, tabletting, coating is processed 1000 in tablet.
Embodiment 7: the preparation of capsule
Get crude drug by weight proportion: Radix Notoginseng 30g, Rhizoma Chuanxiong 30g, Flos Carthami 30g, Semen Persicae 30g, Radix Puerariae 90g, Fructus Crataegi flavone 50g, gypenoside 50g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and Fructus Crataegi flavone, gypenoside mix homogeneously with according to the above ratio add suitable adjuvant, stir, and granulate, and granulate is filled, and processes 1000 of capsules.
Embodiment 8: the preparation of granule
Get crude drug by weight proportion: Radix Notoginseng 60g, Rhizoma Chuanxiong 60g, Flos Carthami 70g, Semen Persicae 70g, Radix Puerariae 200g, Fructus Crataegi flavone 60g, gypenoside 60g.
Medical material is made only, fragmentation.Get Radix Notoginseng powder according to the above ratio and be broken into fine powder, subsequent use; Get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8 times of water gagings and decoct and extract 2 times, each 2 hours, merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature, and is subsequent use;
Other gets subsequent use Radix Notoginseng fine powder and thick paste mixing, 70 ℃ of dryings, and dried cream powder is broken to sieve, and Fructus Crataegi flavone, gypenoside mix homogeneously with according to the above ratio add suitable adjuvant, stir, and process granule 1000g.
The present invention can also process other suitable pharmaceutical dosage form.
Pharmacological research:
1, embodiment 1-6 is to the influence of rat platelet cohesion function
80 of male rats about body weight 220g, are divided into 8 groups, 10 every group at random: 1. model group is given normal saline, 2. aspirin group, and 3. embodiment 1, and 4. embodiment 2, and 5. embodiment 3, and 6. embodiment 4, and 7. embodiment 5, and 8. embodiment 6.Dosage such as following table, ig administration, 1 time/d, continuous 7d (aspirin group 4d); 1h after the last administration, anesthesia, the ventral aorta blood sampling, preparation platelet rich plasma and platelet poor plasma are measured the maximum coagulation rate of platelet in the 5min with platelet aggregation instrument.The result sees table 6:
Table 6 preparation of the present invention influences result (
n=10) to rat platelet cohesion function
Annotate: compare with model group,
※P＜0.01,
ZeroP＜0.05.
The result shows that preparation of the present invention has the obvious suppression effect to the maximum coagulation rate of rat platelet.
2, the influence of 5 pairs of rat platelet cohesions of most preferred embodiment function
50 of male rats about body weight 220g, are divided into 5 groups, 10 every group at random: 1. model group, give the 2. 3. 4. 5. heavy dose of group of embodiment 5 preparations of dose groups in embodiment 5 preparations of embodiment 5 preparation small dose group of aspirin group of normal saline.Dosage such as following table, ig administration, 1 time/d, continuous 7d (aspirin group 4d); 1h after the last administration, anesthesia, the ventral aorta blood sampling, preparation platelet rich plasma and platelet poor plasma are measured the maximum coagulation rate of platelet in the 5min with platelet aggregation instrument.The result sees table 7:
Table 7 preparation of the present invention influences result (
n=10) to rat platelet cohesion function
Annotate: compare with matched group,
※P＜0.01,
ZeroP＜0.05.
The result shows that preparation of the present invention has the obvious suppression effect to the maximum coagulation rate of rat platelet.
3, to the influence of blood stasis model rat blood rheological characteristic
60 of rats, male and female half and half, about body weight 220g, divide equally 6 groups, 10 every group: 1. normal group, give the 2. 3. 4. real 6. heavy dose of group of embodiment 5 preparations of dose groups of 5. executing in routine 5 preparations of embodiment 5 preparation small dose group of aspirin group of model group of normal saline.Dosage such as following table, ig administration, 1 time/d, continuous 8d (aspirin administration 5d); 30min after the 7d administration, sc epinephrine 0.9mg/kg, the rearmounted ice-water bath cooling of 30min 8min dries water on one's body; Sc equivalent epinephrine again after for the first time injecting epinephrine 4h is handled the back fasting and can't help water, and 60min after last administration in the 8th day is under anesthesia; Ventral aorta blood sampling 5ml puts and surveys its whole blood viscosity and blood plasma viscosity in the blood viscosity appearance, and the result sees table 8:
Table 8 preparation of the present invention influences result (
n=10) to blood stasis model rat blood rheological characteristic
Annotate: compare with model group,
※P＜0.01,
ZeroP＜0.05.
The result shows that single all indexs of giving adrenergic rat show the model establishment all than the obvious rising of matched group.Administration group rat index all has reduction in various degree, shows the preparation of the present invention blood stasis effect that has clear improvement.
4, to the influence of aged mouse anti-oxidation function
Aged kunming mice was 40 in 15 months, about body weight 40g, was divided into 4 groups at random, 10 every group: 1. model group, give the 2. 3. 4. heavy dose of group of embodiment 5 preparations of dose groups in embodiment 5 preparations of embodiment 5 preparation small dose group of normal saline.Dosage such as following table, ig administration, 1 time/d, continuous 1 month.After the off-test, get the mouse brain tissue, preparation brain tissue homogenate liquid, thiobarbituricacid spectrophotometry MDA product malonaldehyde (MDA) content, the xanthine oxidase of improvement is measured superoxide dismutase (SOD) content.The result sees table 9:
Table 9 preparation of the present invention influences result (
n=10) to the aged mouse anti-oxidation function
Annotate: compare with matched group,
※P＜0.05.
Experimental result shows that MDA content reduces in the mouse brain tissue, and SOD content improves, and shows that Chinese medicine preparation of the present invention has the effect that improves anti-oxidation function.
Claims (8)
1. be used to prevent and treat the medicine of Alzheimer and cerebral thrombosis, it is characterized in that: its raw material mainly is made up of the following weight ratio:
Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part.
2. the medicine that is used to prevent and treat Alzheimer and cerebral thrombosis according to claim 1 is characterized in that: its raw material is made up of the following weight ratio:
49 parts of Radix Notoginseng, 49 parts of Rhizoma Chuanxiongs, 57.5 parts on Flos Carthami, 57.5 parts in Semen Persicae, 164 parts of Radix Puerariaes.
3. the medicine that is used to prevent and treat Alzheimer and cerebral thrombosis according to claim 1 is characterized in that: its raw material is made up of the following weight ratio:
Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part, Fructus Crataegi flavone 50-150 part, gypenoside 50-150 part.
4. the medicine that is used to prevent and treat Alzheimer and cerebral thrombosis according to claim 1 is characterized in that: its raw material weight ratio is:
49 parts of Radix Notoginseng, 49 parts of Rhizoma Chuanxiongs, 57.5 parts on Flos Carthami, 57.5 parts in Semen Persicae, 164 parts of Radix Puerariaes, 90 parts of Fructus Crataegi flavone, 90 parts of gypenosides.
5. according to each described medicine that is used to prevent and treat Alzheimer and cerebral thrombosis of claim 1-4, it is characterized in that: its described medicine is used for prevention and treatment Alzheimer and cerebral thrombosis.
6. be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis, it is characterized in that: get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part; Flos Carthami 30-120 part, Semen Persicae 30-120 part, Radix Puerariae 90-360 part; Medical material is made only fragmentation;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously; 60-80 ℃ of drying, dried cream powder is broken to sieve, and processes medicine by the industry routine.
7. be used to prevent and treat the method for preparing of the medicine of Alzheimer and cerebral thrombosis; It is characterized in that: get crude drug by weight proportion: Radix Notoginseng 30-120 part, Rhizoma Chuanxiong 30-120 part, Flos Carthami 30-120 part; Semen Persicae 30-120 part; Radix Puerariae 90-360 part, Fructus Crataegi flavone 50-150 part, gypenoside 50-150 part; Medical material is made only fragmentation;
1) get Radix Notoginseng according to the above ratio, be ground into fine powder, subsequent use;
2) get the Flos Carthami of Rhizoma Chuanxiong, Semen Persicae, Radix Puerariae, gauze parcel according to the above ratio, add 8-12 times of water gaging and decoct and extract 1-3 hour at every turn 1-3 time; Merge the water extract, filter, relative density is the thick paste of 1.30-1.35 when being evaporated to 60 ℃ of temperature; Thick paste and 1) a subsequent use fine powder mix homogeneously, 60-80 ℃ of drying, dried cream powder is broken to sieve; With Fructus Crataegi flavone, gypenoside mix homogeneously according to the above ratio, process medicine by the industry routine.
8. according to claim 6 or the 7 described method for preparinies that are used to prevent and treat the medicine of Alzheimer and cerebral thrombosis, it is characterized in that: wherein said medicine is tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110331011 CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110331011 CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102357134A true CN102357134A (en) | 2012-02-22 |
| CN102357134B CN102357134B (en) | 2013-05-01 |
Family
ID=45582551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110331011 Active CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102357134B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949527A (en) * | 2012-11-23 | 2013-03-06 | 周纯喜 | Traditional Chinese medicinal preparation for treating senile dementia and corresponding preparation method |
| CN102988697A (en) * | 2012-08-21 | 2013-03-27 | 苏州谷力生物科技有限公司 | Composition having antithrombosis effect |
| CN103083558A (en) * | 2013-01-10 | 2013-05-08 | 山东凤凰制药股份有限公司 | Novel application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
| CN103931792A (en) * | 2014-03-21 | 2014-07-23 | 安徽省怀远县鑫泰粮油有限公司 | Cardiovascular and cerebrovascular disease preventing peanut oil and its preparation method |
-
2011
- 2011-10-27 CN CN 201110331011 patent/CN102357134B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 《中华中医药学刊》 20070930 金李君等 绞股蓝皂苷对糖尿病肾病大鼠肾组织转化生长因子beta1表达的影响 1922-1925 3-5 第25卷, 第9期 * |
| 文莉等: "脑得生抗血栓处方筛选", 《中国医院药学杂志》 * |
| 郭永学等: "山楂属植物黄酮成分及其分析方法研究进展", 《中成药》 * |
| 金李君等: "绞股蓝皂苷对糖尿病肾病大鼠肾组织转化生长因子β1表达的影响", 《中华中医药学刊》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988697A (en) * | 2012-08-21 | 2013-03-27 | 苏州谷力生物科技有限公司 | Composition having antithrombosis effect |
| CN102949527A (en) * | 2012-11-23 | 2013-03-06 | 周纯喜 | Traditional Chinese medicinal preparation for treating senile dementia and corresponding preparation method |
| CN103083558A (en) * | 2013-01-10 | 2013-05-08 | 山东凤凰制药股份有限公司 | Novel application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
| CN103931792A (en) * | 2014-03-21 | 2014-07-23 | 安徽省怀远县鑫泰粮油有限公司 | Cardiovascular and cerebrovascular disease preventing peanut oil and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102357134B (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Progress in the treatment of diabetic peripheral neuropathy | |
| CN113577230A (en) | Composition for preventing and delaying occurrence and development of senile dementia and application thereof | |
| CN103071048A (en) | Traditional Chinese medicine composition for treating alzheimer diseases and preparation method of traditional Chinese medicine composition | |
| CN102357134B (en) | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| Zhang et al. | Neuroprotective effects of Morinda officinalis How.: Anti-inflammatory and antioxidant roles in Alzheimer’s disease | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN104147345B (en) | A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy | |
| CN103520318B (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| Garg et al. | Pharmacology of polygala tenuifolia and its significance in traditional Chinese medicine | |
| CN1369289A (en) | Chinese medicine for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN101274013A (en) | Prescription medicine for curing senile dementia and preparation | |
| CN103638304A (en) | Traditional Chinese medicine preparation for treating liver yang rising type migraine and preparation method thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN105435196A (en) | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
| CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
| CN110339293A (en) | A kind of arteries and veins gel resin capsule formula and preparation process | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN103656318B (en) | One treats migrainous Chinese medicine preparation of essential resistance of turbid phlegm type and preparation method thereof | |
| CN103860877A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120222 Assignee: Hengshengtang Pharmaceutical Co., Ltd., Xi'an City Assignor: Chen Rende Contract record no.: 2015610000026 Denomination of invention: Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof Granted publication date: 20130501 License type: Exclusive License Record date: 20150422 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180314 Address after: 710043 Shaanxi province Xi'an city street Shinco Weishen Road No. 1 park on the eighth floor of block B Patentee after: Hengshengtang Pharmaceutical Co., Ltd., Xi'an City Address before: 710043 Shaanxi province Xi'an city street Shinco Weishen Road No. 1 Metro Technology Industrial Park Industrial Park Building 8 floor B block Patentee before: Chen Rende |
|
| TR01 | Transfer of patent right |